Loading
Statistician behind the Early Breast Cancer Trialists' meta-analyses that set the global evidence base for adjuvant therapy.
Richard Gray leads the secretariat of the Early Breast Cancer Trialists' Collaborative Group, whose individual-patient-data meta-analyses of hundreds of trials quantified the benefits of tamoxifen, aromatase inhibitors, chemotherapy, radiotherapy and bisphosphonates and underpin every breast cancer guideline. He also led the QUASAR colorectal adjuvant trials and the aTTom trial of ten years of tamoxifen.
Shares HR-positive / HER2-negative breast cancer and the tags biostatistics, breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.